BIOA News

Sales of Leqembi® totaled 29.3 billion yen in the second quarter 2026

More than 75% of Leqembi®-treated patients remained stable and nearly 7% improved over an average of 17 months of treatment in real-world LEADER study data presented at AAIC® 2026

BioAge Labs administra la primera dosis a un participante en el ensayo de fase 2 de BGE-102

BioAge Labs, partenaire de HitGen, a administré la première dose à un participant dans le cadre de l'essai de phase 2 du BGE-102, un nouvel inhibiteur oral de NLRP3 destiné à réduire les risques cardiovasculaires

BioAge Labs, Partner von HitGen, verabreicht erste Dosis an Teilnehmer der Phase-2-Studie zu BGE-102, einem neuartigen oralen NLRP3-Inhibitor zur Senkung des kardiovaskulären Risikos

HitGen Partner BioAge Labs Doses First Participant in Phase 2 Trial of BGE-102, a Novel Oral NLRP3 Inhibitor for Cardiovascular Risk Reduction

BioAge Labs Announces First Participant Dosed in QUELL-CV, a Phase 2 Proof-of-Concept Trial of BGE-102, a Novel Oral NLRP3 Inhibitor, in Patients at Elevated Cardiovascular Risk

Form 8-K

Number of shares and votes in BioArctic AB (publ) as of May 29, 2026

Bulletin from the Annual General Meeting in BioArctic AB (publ) USA - English USA - English